Cancer-testis antigens (CTAs) are a class of cancer antigens with extensive expression in human cancers. Many researchers have detected antibody responses against these tumor antigens in serum of cancer patients.
OBJECTIVES:
To evaluate the relevance of humoral immune responses against CTAs in clinical outcome of cancer patients
METHODS:
We searched PubMed/Medline with the key words cancer-testis antigen, antibody, humoral response and cancer.
RESULTS:
Humoral immune responses against CTAs have been detected in several human malignancies including skin, breast, brain and ovarian cancers. Some studies have shown associations between the presence of these responses in patients and patients’ survival.
CONCLUSION:
Humoral immune responses against CTAs are putative biomarkers for cancer detection and follow-up.
Ghafouri-FardS. and ModarressiM.H., Cancer-testis antigens: potential targets for cancer immunotherapy, Archives of Iranian Medicine12 (Jul 2009), 395.
2.
FrattaE. et al., The biology of cancer testis antigens: Putative function, regulation and therapeutic potential, Mol Oncol5 (Apr 2011), 164.
3.
Ghafouri-FardS.RezazadehF.Zare-AbdollahiD.OmraniM.D. and MovafaghA., Are so-called cancer-testis genes expressed only in testis, Asian Pac J Cancer Prev15 (2014), 7703.
4.
BabatundeK.A.NajafiA.SalehipourP.ModarressiM.H. and MobasheriM.B., Cancer/Testis genes in relation to sperm biology and function, Iran J Basic Med Sci20 (Sep 2017), 967.
5.
OhueY.WadaH.OkaM. and NakayamaE., Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients, Oncoimmunology3 (Nov 2014), e970032.
6.
OhueY. et al., Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research20 (1 Oct 2014), 5052.
7.
DaudiS.Expression, et al. and immune responses to MAGE antigens predict survival in epithelial ovarian cancer, PloS One9 (2014), e104099.
8.
FujiwaraS. et al., NY-ESO-1 antibody as a novel tumour marker of gastric cancer, British Journal of Cancer108 (19 Mar 2013), 1119.
9.
DianatpourM. et al., Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer, Iranian Red Crescent Medical Journal14 (Nov 2012), 722.
10.
Ghafouri-FardS.ShamsiR.Seifi-AlanM.JavaheriM. and TabarestaniS., Cancer-testis genes as candidates for immunotherapy in breast cancer, Immunotherapy6 (2014), 165.
11.
Seifi-AlanM. et al., Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines, Asian Pac J Cancer P14 (2013), 6625.
12.
Kazemi-OulaG.Ghafouri-FardS.MobasheriM.B.GeranpayehL. and ModarressiM.H., Upregulation of RHOXF2 and ODF4 expression in breast cancer tissues, Cell Journal (Yakhteh)17 (2015), 471.
13.
AdemuyiwaF.O. et al., NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer, PloS One7 (2012), e38783.
14.
HamaiA. et al., Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy, PloS One6 (17 Jun 2011).
15.
StockertE. et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens, The Journal of Experimental Medicine187 (20 Apr 1998), 1349.
16.
OdunsiK., et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer, Cancer Res63 (15 Sep 2003), 6076.
17.
FaramarziS. and Ghafouri-FardS., Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy, Immunotherapy9 (2017), 1019.
18.
Ghafouri-FardS.Ousati AshtianiZ.Sabah GolianB.HasheminasabS.M. and ModarressiM.H., Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer, Archives of Medical Research41 (Apr 2010), 195.
19.
von Boehmer et al.L.,Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy, J Clin Oncol 27(20 May 2009).
20.
ParmigianiR.B. et al., Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence, International Journal of Cancer122 (15 May 2008), 2385.
21.
FaramarziS. and Ghafouri-FardS., Melanoma: A prototype of cancer-testis antigen-expressing malignancies, Immunotherapy9 (Oct 2017), 1103.
22.
Ghafouri-FardS. and Ghafouri-FardS., Immunotherapy in nonmelanoma skin cancer, Immunotherapy4 (2012), 499.
23.
Ghafouri-FardS. et al., Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features, British Journal of Dermatology162 (2010), 772.
24.
OunapK. et al., Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma, Oncol Lett16 (Jul 2018), 211.
25.
Ghafouri-FardS.NekooheshL. and MotevaseliE., Bladder cancer biomarkers: Review and update, Asian Pac J Cancer P15 (2014), 2395.
26.
YazarlouF. et al., Expression analysis of a panel of cancer-testis antigens in bladder cancer, Pers Med15 (Nov 2018), 511.
27.
YazarlouF. et al., Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma, Cancer Management and Research10 (2018), 5373.
28.
JagerE. et al., Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events, International Journal of Cancer84 (22 Oct 1999), 506.
29.
Ghafouri-FardS. and ModarressiM.-H., Expression of cancer–testis genes in brain tumors: implications for cancer immunotherapy, Immunotherapy4 (2012), 59.
30.
Ghafouri-FardS., Expression of cancer-testis antigens in stem cells: is it a potential drawback or an advantage in cancer immunotherapy, Asian Pac J Cancer Prev16 (2015), 3079.
31.
BettoniF. et al., Identification of FAM46D as a novel cancer/testis antigen using EST data and serological analysis, Genomics94 (Sep 2009), 153.
32.
Seifi-AlanM.ShamsiR. and Ghafouri-FardS., Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma, Immunotherapy10 (Apr 2018), 411.
33.
MonjiM. et al., Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research10 (15 Sep 2004), 6047.
34.
DongX.Y. et al., Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients, British Journal of Cancer89 (21 Jul 2003), 291.
35.
ZhangJ.Y. et al., Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies, Clinical Immunology (Orlando, Fla )100 (Aug 2001), 149.
36.
YinY.H. et al., TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma, British Journal of Cancer93 (22 Aug 2005), 458.
37.
NakamuraS., et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma, Journal of Gastroenterology and Hepatology21 (Aug 2006), 1281.
38.
DongX.Y. et al., Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients, International Journal of Cancer122 (1 May 2008), 2038.
39.
TanakaR. et al., Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity, Microbiology and Immunology48 (2004), 339.
40.
DongX.Y.YangX.A.WangY.D. and ChenW.F., Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients, British Journal of Cancer91 (18 Oct 2004), 1566.
41.
Ghafouri-FardS.ModarressiM.H. and YazarlooF., Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity, Ann Saudi Med32 (May–Jun 2012), 256.
42.
Ghafouri-FardS.Seifi-AlanM.ShamsiR. and EsfandiaryA., Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens, Iran J Cancer Prev8 (Oct 2015).
43.
NishikawaH. et al., Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma, Blood119 (29 Mar 2012), 3097.
44.
InaokaR.J. et al., Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients, Cancer Immunology, Immunotherapy: CII61 (Dec 2012), 2207.
45.
RosenzweigM.A. et al., Cancer-testis antigen expression and immunogenicity in AL amyloidosis, Blood Cancer Journal2 (14 Sep 2012), e90.
46.
TabarestaniS. and Ghafouri-FardS., Cancer Stem Cells and Response to Therapy, Asian Pac J Cancer P13 (2012), 5947.
47.
EsfandiaryA. and Ghafouri-FardS., New York esophageal squamous cell carcinoma-1 and cancer immunotherapy, Immunotherapy7 (2015), 411.
48.
EsfandiaryA. and Ghafouri-FardS., MAGE-A3: An immunogenic target used in clinical practice, Immunotherapy7 (2015), 683.
49.
AzamR. et al., Lactobacillus acidophilus and Lactobacillus crispatus Culture Supernatants Downregulate Expression of Cancer-testis Genes in the MDA-MB-231 Cell Line, Asian Pac J Cancer P15 (2014), 4255.
